Scientific Program
Friday, September 12, 2025
| 08:00-08:15 |
Congress Opening |
Sala San Martin |
|
Welcome message on behalf of the Congress chairpersons
Bruce Mann, Melbourne, Australia
Alastair Thompson, Houston, TX, USA
Henry Gomez, Lima, Peru
Luis Pinillos, Lima, Peru
Mauricio León, Lima, Peru |
| 08:15-09:30 |
Session 1: Neoadjuvant therapy |
Sala San Martin |
| Chairpersons |
Bruce Mann, Melbourne, Australia
Carlos Vallejos, Lima, Peru
|
08:15-08:45
08:15
08:25
08:35 |
Debate: That cT1cN0 HER2+ve should have Neoadjuvant Systemic Therapy (NAST)
Yes: Javier Cortes, Madrid, Spain
No: Richard de Boer, Melbourne, Australia
Discussion |
| 08:45-09:00 |
Didactic: Imaging before and during NAST
Karla Sepulveda, Houston, TX, USA |
09:00-09:30
09:00
09:10
09:20 |
Debate: That endocrine therapy is neoadjuvant treatment of choice for ER+ve/HER2-ve disease
Yes: Antonio Llombart, Valencia, Spain
No: Henry Gomez, Lima, Peru
Discussion |
| 09:30-10:15 |
Mid-morning Symposium
Supported by MSD
|
Sala San Martin |
| Topic |
Controversies in neoadjuvant and adjuvant management of triple negative breast cancer |
| Speaker |
Luis Schwarz, Lima, Peru |
| 10:15-10:45 |
Coffee break, poster viewing and exhibition visit |
| 10:45-11:45 |
Session 2: Surgery |
Sala San Martin |
| Chairpersons |
Luis Pinillos, Lima, Peru
Rafael Vázquez, Mexico City, Mexico
|
10:45-11:15
10:45
10:55
11:05 |
Debate: Breast conservation, not mastectomy, should be the standard of care for T2 cancers
Yes: Stuart McIntosh, Belfast, UK
No: Nereida Esparza, Mexico City, Mexico
Discussion |
11:15-11:45
11:15
11:25
11:35 |
Debate: Radiation therapy should be given to all women under 70 having breast conservation for invasive cancer
Yes: David Martínez, Medellin-Antioquia, Colombia
No: Mauricio León, Lima, Peru
Discussion |
| 11:45-12:45 |
Session 3: Screening |
Sala San Martin |
| Chairpersons |
Liana Falcón, Lima, Peru
Gerardo Castorena, Mexico City, Mexico |
11:45-12:15
11:45
11:55
12:05 |
Debate: Is there still a role for mammography in the era of advanced imaging?
Yes: Karla Sepulveda, Houston, TX, USA
No: Cilia Farias, Lima, Peru
Discussion |
| 12:15-12:45 |
Didactic: Artificial Intelligence to advance breast cancer screening
Karla Sepulveda, Houston, TX, USA |
| 12:45-13:45 |
Lunch break, poster viewing and exhibition visit |
| 13:45-14:15 |
Session 4: Case Discussion
Redefining the management of early-stage breast cancer |
Sala San Martin |
Case
Presenter/
Moderator |
Pamela Rebaza, Lima, Peru |
| Panel of experts |
Imager: Rosa Cebrian, Lima, Peru
Medical oncologist: Zaida Morante, Lima, Peru
Surgeon: Yanet Carrasco, Arequipa, Peru
Radiation oncologist: Joseana Ayala, Lima, Peru
Pathologist: Andrea Gomero, Lima, Peru
Medical oncologist: Antonio Llombart, Valencia, Spain
Surgeon: Stuart McIntosh, Belfast, UK
|
| 14:15-15:45 |
Session 5: HER2+ve disease |
Sala San Martin |
| Chairpersons |
Adriana Freitas, Santa Catarina, Brazil
Javier Cortes, Madrid, Spain |
14:15-14:45
14:15
14:25
14:35 |
Debate: Do anthracyclines still have a place in the treatment of early stage HER2+ve BC?
Yes: Antonio Llombart, Valencia, Spain
No: Richard de Boer, Melbourne, Australia
Discussion |
14:45-15:15
14:45
14:55
15:05 |
Didactic: Understanding HER2 low disease – how to diagnose/how to treat?
Diagnose: Nirmala Pathmanathan, Sydney, Australia
Treat: Luis Schwarz, Lima, Peru
Discussion |
15:15-15:45
15:15
15:25
15:35 |
Debate: Axillary radiation is better than surgery for residual node positive disease after neoadjuvant treatment
Yes: Gustavo Luyo, Lima, Peru
No: Stuart McIntosh, Belfast, UK
Discussion |
| 15:45-16:30 |
Mid-afternoon Symposium
Supported by AstraZeneca |
Sala San Martin |
| Topic |
HER2-low and ultra-low in metastatic breast cancer |
| Speakers |
Silvia Falcón, Lima, Peru
Enrique Alanya, Lima, Peru
|
| 16:30-16:50 |
Coffee break, poster viewing and exhibition visit |
| 16:50-17:50 |
Session 6: HR+ve Metastatic Breast Cancer (MBC) |
Sala San Martin |
| Chairpersons |
Daniel Lee Kay Pen, Lima, Peru
Natalia Valdivieso, Lima, Peru |
16:50-17:20
16:50
17:00
17:10 |
Debate: Endocrine therapy should be given as 1st line therapy for ALL patients with ER+ve MBC
Yes: Gerson Mejia, Cochabamba, Bolivia
No: Walter Li, Lima, Peru
Discussion |
17:20-17:50
17:20
17:27
17:34
17:41 |
Didactic: What to do after first progression of ER+ breast cancer on three continents: Change ET, CDK4/6i or SERDS?
Javier Cortes, Madrid, Spain
Richard de Boer, Melbourne, Australia
Natalia Valdivieso, Lima, Peru
Discussion |
| 17:50-19:00 |
Poster Session |
| 19:00-21:00 |
Welcome Reception will take place at The Terrace (La Terraza) |
Saturday, September 13, 2025
| 08:30-09:30 |
Session 7: ER+ breast cancer
|
Sala San Martin |
| Chairpersons |
Enrique Bargallo, Mexico City, Mexico
Alastair Thompson, Houston, TX, USA |
08:30-09:00
08:30
08:40
08:50
|
Debate: In postmenopausal women who are candidates for extended therapy, only an aromatase inhibitor should be used
Yes: Gerson Mejia, Cochabamba, Bolivia
No: Silvia Falcón Lima, Peru
Discussion |
09:00-09:30
09:00
09:10
09:20 |
Debate: Postmenopausal women with clinical T1N0 ER+ breast cancer do not need axillary surgery
Yes: Pamela Rebaza, Lima, Peru
No: Bruce Mann, Melbourne, Australia
Discussion |
| 09:30-10:15 |
Mid-morning Symposium
Supported by Prelude DX and Ambios |
Sala San Martin |
| Topic |
Limitations of clinicopathology and why DCISionRT is changing practice in DCIS radiation decisions |
| Speaker |
Bruce Mann, Melbourne, Australia |
| 10:15-10:45 |
Coffee break, poster viewing and exhibition visit |
| 10:45-11:45 |
Session 8: Triple negative breast cancer |
Sala San Martin |
| Chairpersons |
Richard De Boer, Melbourne, Australia
Stuart McIntosh, Belfast, UK |
10:45-11:15
10:45
10:55
11:05 |
Debate: That all stage 2 TNBC patients should be treated according to the Keynote 522 regimen
Yes: Javier Cortes, Madrid, Spain
No: Henry Gomez, Lima, Peru
Discussion |
| 11:15-11:45 |
Didactic: TNBC subtypes: How do we use them to help patient outcomes?
Nirmala Pathmanathan, Sydney, Australia |
| 11:45-12:15 |
Session 9: Case Discussion
Early HER2 breast cancer: When less is more – a case report |
Sala San Martin |
Case Presenter/
Moderator |
Ronald Limon, Santa Cruz de la Sierra, Bolivia |
| Panel of experts |
Imager: Liana Falcón, Lima, Peru
Medical oncologist: Natalia Valdivieso, Lima, Peru
Surgeon: Andy Pantoja, Trujillo, Peru
Radiation oncologist: Alberto Lachos, Lima, Peru
Pathologist: Franco Doimi, Lima, Peru
Medical oncologist: Javier Cortes, Madrid, Spain
Medical oncologist: Richard de Boer, Melbourne, Australia |
| 12:15-13:15 |
Session 10: Reducing the risk |
Sala San Martin |
| Chairpersons |
Karla Sepulveda, Houston, TX, USA
Mauricio León, Lima, Peru |
12:15-12:45
12:15
12:25
12:35 |
Debate: All women under 50 with gene mutations should be offered bilateral mastectomy
Yes: Pamela Rebaza, Lima, Peru
No: Stuart McIntosh, Belfast, UK
Discussion |
12:45-13:15
12:45
12:55
13:05 |
Debate: All women presenting with nodal disease should have radiation therapy after mastectomy
Yes: Oscar Niño De Guzman, Cochabamba, Bolivia
No: Valentina Ovalle, Santiago, Chile
Discussion |
| 13:15-14:15 |
Lunch break, poster viewing and exhibition visit |
| 14:15-15:45 |
Session 11: Adjuvant endocrine therapy |
Sala San Martin |
| Chairpersons |
Nirmala Pathmanathan, Sydney, Australia
Rafael Vázquez, Mexico City, Mexico
|
| 14:15-14:55 |
Pitching the test in five minutes: Why this test is “best”? |
| 14:15
14:25
14:35
14:45 |
PAM50: Javier Cortes, Madrid, Spain
Oncotytpe/ODX: Henry Gomez, Lima, Peru
Mammaprint: Alastair Thompson, Houston, TX, USA
Pathology: Henry Guerra, Lima, Peru |
| 14:55-15:15 |
Didactic: Risk assessment (summary) for ER+ breast cancer
Antonio Llombart, Valencia, Spain |
15:15-15:45
15:15
15:25
15:35 |
Debate: That all young women treated with OFS should be given an aromatase inhibitor
Yes: Alastair Thompson, Houston, TX, USA
No: Richard De Boer, Melbourne, Australia
Discussion |
| 15:45-16:30 |
Mid-afternoon Symposium
Supported by Novartis |
Sala San Martin |
| Topic |
Optimizing the management of early HR+ breast cancer: Evidence and perspectives |
| Speaker |
Henry Gomez, Lima, Peru |
| 16:30-16:50 |
Coffee break, poster viewing and exhibition visit |
| 16:50-17:50 |
Session 12: Locoregional management |
Sala San Martin |
| Chairpersons |
Pamela Rebaza, Lima, Peru
Alastair Thompson, Houston, TX, USA
|
16:50-17:20
16:50
17:00
17:10 |
Debate: That patients with heavy axillary nodal disease pre-NACT should have axillary dissection irrespective of response to NACT
Yes: Enrique Bargallo, Mexico City, Mexico
No: Bruce Mann, Melbourne, Australia
Discussion |
| 17:20-17:50 |
Case Discussion: Focusing on locoregional management |
Case
Presenter/
Moderator |
Mauricio León, Lima, Peru |
| Panel of experts |
Medical oncologist: Luis Orrego, Lima, Peru
Imager: Pilar Montenegro, Lima, Peru
Surgeon: Oscar Niño De Guzman, Cochabamba, Bolivia
Radiation oncologist: Juan Manuel Trejo, Lima, Peru
Pathologist: Henry Guerra, Lima, Peru
Surgeon: Alastair Thompson, Houston, TX, USA
Surgeon: Stuart McIntosh, Belfast, UK |
| 17:50-18:00 |
Congress closing and Award presentation |
Sala San Martin |
|
Bruce Mann, Melbourne, Australia
Alastair Thompson, Houston, TX, USA
Henry Gomez, Lima, Peru
Luis Pinillos, Lima, Peru
Mauricio León, Lima, Peru |
- Program is subject to change
